Physician profile
Christopher A Sanchez
NPI 1558656025
$1,442.73
in general payments reported to CMS, 2019-2025
32 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $256 · 2021: $249 · 2022: $158 · 2023: $193 · 2024: $161 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $200.93 | 2019-2022 | |
| Smith+Nephew, INC. | $135.87 | 2019-2022 | |
| Stryker Corporation | $122.70 | 2021-2025 | Mako, Accolade, X3 |
| Pacira Therapeutics, INC. | $105.81 | 2019-2020 | |
| Grifols USA, LLC | $104.60 | 2019-2023 | Gamunex-C |
| Biocomposites INC | $62.78 | 2023 | Stimulan |
| Pacira Pharmaceuticals Incorporated | $57.92 | 2020-2025 | Exparel, Iovera, Zilretta |
| Zimmer Biomet Holdings, INC. | $51.09 | 2021 | |
| Abbvie INC. | $46.44 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $45.48 | 2024-2025 | |
| Csl Behring | $44.16 | 2023-2024 | Hizentra |
| Kyowa Kirin, INC. | $39.89 | 2022-2024 | Nourianz |
| Paratek Pharmaceuticals, INC. | $38.50 | 2022 | |
| Upsher-Smith Laboratories LLC | $32.17 | 2019-2021 | |
| Dynasplint Systems INC. | $31.05 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $28.00 | 2024 | Sx-One Microknife |
| Avanos Medical | $27.17 | 2019 | |
| Spr Therapeutics, INC | $24.05 | 2024 | Sprint Pns System |
| Biotissue Holdings INC. | $21.89 | 2021 | |
| Sanara Medtech INC. | $21.51 | 2022 | |
| Lundbeck LLC | $21.11 | 2023 | Vyepti |
| Neurocrine Biosciences, INC. | $19.76 | 2021 | |
| Grt US Holding, INC. | $19.53 | 2020 | |
| Vericel Corporation | $18.37 | 2021 | |
| Sentynl Therapeutics, INC. | $17.44 | 2019 | |
| Baudax Bio INC. | $17.03 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.51 | 2025 | Euflexxa |
| Ibsa Pharma INC. | $16.28 | 2023 | Tirosint, Licart |
| Depuy Synthes Sales INC. | $15.54 | 2021 | |
| Convatec INC. | $14.89 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.22 | 2023 | |
| Ermi LLC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.